PO.MCB08.03 · 分子与细胞生物学

人类与犬神经鞘肿瘤在形态学、预后、治疗、表观遗传学、转录组学和基因组学方面的比较研究

Comparative study of human and canine nerve sheath tumors in terms of morphology, prognosis, treatment, epigenetics, transcriptomics, and genomics

海报缩略图:人类与犬神经鞘肿瘤在形态学、预后、治疗、表观遗传学、转录组学和基因组学方面的比较研究
编号 3250 展板 15 时间 4/20 02:00–05:00 区域 Section 22 主讲 Emily Keung, MD
分会场 Genomic Profiling to Understand Cancer Biology
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jace P. Landry1, Angela D. Bhalla1, Sharon M. Landers1, Rossana Lazcano1, Lindsay A. Parker2, Tasha M. Miller2, Noelle Niemi2, Heather G. Lyu1, Heather A. Lillemoe1, Emily Z. Keung1, Christopher P. Scally1, Christina L. Roland1, Kelly K. Hunt1, John M. Slopis1, Ian E. McCutcheon1, Beth Boudreau2, Heather Wilson-Robles2, Alexander J. Lazar1, Kunal Rai1, Dominique J. Wiener2, Brian W. Davis2, Brandan Wustefeld-Janssens2, Keila E. Torres1

1UT MD Anderson Cancer Center, Houston, TX,2Texas A&M University, College Station, TX

摘要 Abstract

中文摘要
引言:恶性外周神经鞘肿瘤(MPNST)是侵袭性肉瘤。治疗MPNST的一大障碍是缺乏有效的全身性疗法。尽管超过70%的人类MPNST丢失或失活了表观基因组调控因子多梳抑制复合物2(PRC2)(DeRaedt等,《Nature》,2014),但其在犬PNST进展中的活性和作用仍不明确。 方法:本研究比较了犬外周神经鞘肿瘤(PNST)和人类MPNST在生物学和临床特征方面的差异,包括PRC2活性。对包含54例神经纤维瘤和139例MPNST的人类组织微阵列以及63例犬PNST进行了免疫组化分析,检测H3K27me3(由完整PRC2沉积的抑制性组蛋白标记)和H3K27ac(在H3K27me3丢失后全局性升高)。为了解犬PNST中存在的基因组改变,我们分析了8对犬PNST/正常配对样本的肿瘤突变负荷、拷贝数改变和转录组。 结果:结果提示H3K27me3丢失及相关的H3K27ac获得从表观遗传学上驱动了人类和犬的肿瘤。本研究提供了证据,表明人类和犬PNST在临床病理学上相似,也可能同样由表观遗传机制驱动。 结论:有必要进行进一步研究,以评估这些表观遗传失调是否在人类和犬患者中改变了相似的基因特征。本研究所获得的知识增进了我们对MPNST分子驱动因素的理解,并为未来临床研究中值得评估的潜在疗法提供了信息。
查看英文原文 English abstract
INTRODUCTION: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas. An obstacle to treating MPNSTs is a lack of effective systemic therapies. Although over 70% of human MPNSTs have lost or inactivated the epigenome regulator polycomb repressive complex 2 ( PRC2 ) (DeRaedt et al. , Nature , 2014), its activity and contribution to canine PNST progression remain unclear. METHODS: This study compared canine peripheral nerve sheath tumors (PNSTs) and human MPNSTs across biological and clinical features, including PRC2 activity. Immunohistochemical analysis was performed for a human tissue microarray of 54 neurofibromas and 139 MPNSTs, and 63 canine PNSTs for H3K27me3, a repressive histone mark deposited by intact PRC2, and H3K27ac, which increases globally upon H3K27me3 loss. To understand the genomic alterations present in canine PNSTs, we analyzed tumor mutation burden, copy number alteration, and transcriptomes of eight canine PNST/normal pairs. RESULTS: The results suggested that H3K27me3 loss and associated gain of H3K27ac epigenetically drive human and canine tumors. This study provided evidence that human and canine PNSTs are clinicopathologically similar and may also be similarly driven by epigenetic mechanisms. CONCLUSIONS: Further studies are warranted to evaluate whether these epigenetic deregulations alter similar gene signatures in humans and canine patients. The knowledge gained from this work advances our understanding of the molecular drivers of MPNST and informs potential therapeutics to evaluate in future clinical studies.
利益披露 Disclosure
J. P. Landry, None.. A. D. Bhalla, None.. S. M. Landers, None.. R. Lazcano, None.. L. A. Parker, None.. T. M. Miller, None.. N. Niemi, None.. H. G. Lyu, None.. H. A. Lillemoe, None.. E. Z. Keung, None.. C. P. Scally, None.. C. L. Roland, None.. K. K. Hunt, None.. J. M. Slopis, None.. I. E. McCutcheon, None.. B. Boudreau, None.. H. Wilson-Robles, None.. A. J. Lazar, None.. K. Rai, None.. D. J. Wiener, None.. B. W. Davis, None.. B. Wustefeld-Janssens, None.. K. E. Torres, None.

← 返回 AACR 2026 检索